Thyroid Cancer Treatment Choice: A Pilot Study of a Tool to Facilitate Conversations with Patients with Papillary Microcarcinomas Considering Treatment Options

医学 对话 甲状腺癌 甲状腺 置信区间 甲状腺乳突癌 前瞻性队列研究 家庭医学 癌症 内科学 心理学 沟通
作者
Juan P. Brito,Jae Hoon Moon,Rebecca Zeuren,Sung Hye Kong,Yeo Goon Kim,Nicole M. Iñiguez‐Ariza,June Young Choi,Kyu Eun Lee,Ji‐hoon Kim,Ian Hargraves,Victor Bernet,Víctor M. Montori,Young Joo Park,R. Michael Tuttle
出处
期刊:Thyroid [Mary Ann Liebert]
卷期号:28 (10): 1325-1331 被引量:53
标识
DOI:10.1089/thy.2018.0105
摘要

The 2015 American Thyroid Association guidelines recognize active surveillance as an alternative to immediate surgery in patients with papillary microcarcinomas (PMCs). As a way to incorporate active surveillance as one of the management options for patients with PMCs, we developed and tested a tool to support conversations between clinicians and patients with PMCs considering treatment options.Thyroid Cancer Treatment Choice was developed using an iterative process based on the principles of interaction, design, and participatory action research. To evaluate the impact of the tool on treatment choice, a prospective study was conducted in two thyroid cancer clinics in Seongnam-si and Seoul, South Korea. Both clinics had the expertise to offer active surveillance as well as immediate surgery. One clinic was trained in the use of the conversation aid, while the other clinic continued to care for patients without access to the conversation aid.Between May 2016 and April 2017, 278 patients, mostly women (n = 220, 79%), were included in the study; 152 (53%) received care at the clinic using the conversation aid. Age, sex, and mean (±SD) tumor size (6.6 ± 1.6 mm and 6.5 ± 1.9 mm) distributions were similar across clinics. Overall, 233 (84%) patients opted for active surveillance and 53 (16%) for thyroid surgery. Patients in the conversation aid group were more likely to choose active surveillance than the patients seen in the usual care clinic (relative risk = 1.16 [confidence interval 1.04-1.29]). Of all patients opting for active surveillance, more patients in the conversation aid group had thyroid cancer nodules >5 mm than in the usual care group (81% vs. 67%; p = 0.013).Thyroid Cancer Treatment Choice is an evidence-based tool that supports the presentation of treatment options for PMCs. Pilot testing suggests that this conversation tool increases acceptance of active surveillance, suggesting that this option is an acceptable and preferable alternative for informed patients. Further studies are warranted to confirm this finding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
傻傻的芾发布了新的文献求助10
1秒前
1秒前
1秒前
win发布了新的文献求助10
1秒前
2秒前
bkagyin应助hahaer采纳,获得10
2秒前
科研通AI6.3应助JUSTDOIT采纳,获得10
2秒前
Xiaonian发布了新的文献求助10
2秒前
Akim应助无忧采纳,获得10
2秒前
生动的煎蛋完成签到 ,获得积分10
2秒前
2秒前
糊涂的河马完成签到,获得积分20
2秒前
美美发布了新的文献求助10
3秒前
小软完成签到,获得积分20
3秒前
4秒前
111发布了新的文献求助10
4秒前
皮蛋瘦肉粥完成签到,获得积分10
4秒前
wanci应助abc采纳,获得10
4秒前
生动的水壶完成签到,获得积分10
4秒前
qwe123完成签到,获得积分10
4秒前
4秒前
yangyujie25发布了新的文献求助10
4秒前
5秒前
前扣带回发布了新的文献求助10
5秒前
三泥完成签到,获得积分10
5秒前
hd完成签到,获得积分10
6秒前
6秒前
wenwen发布了新的文献求助10
6秒前
炒米完成签到,获得积分10
7秒前
科目三应助腼腆的尔芙采纳,获得10
7秒前
李健应助科研通管家采纳,获得10
7秒前
ding应助科研通管家采纳,获得10
7秒前
科目三应助科研通管家采纳,获得10
7秒前
FashionBoy应助科研通管家采纳,获得10
7秒前
爆米花应助科研通管家采纳,获得10
7秒前
完美世界应助CYYYY采纳,获得10
7秒前
7秒前
情怀应助科研通管家采纳,获得10
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Handbook of pharmaceutical excipients, Ninth edition 5000
Aerospace Standards Index - 2026 ASIN2026 3000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
Principles of town planning : translating concepts to applications 500
Modified letrozole versus GnRH antagonist protocols in ovarian aging women for IVF: An Open-Label, Multicenter, Randomized Controlled Trial 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6061959
求助须知:如何正确求助?哪些是违规求助? 7894231
关于积分的说明 16308786
捐赠科研通 5205664
什么是DOI,文献DOI怎么找? 2784922
邀请新用户注册赠送积分活动 1767457
关于科研通互助平台的介绍 1647410